Innovent registers Phase III trial of sintilimab with LCCRT in locally advanced rectal cancer
The study, led by Innovent Biologics (Suzhou) Co. Ltd., plans to enroll 500 participants with locally advanced rectal cancer and is planned to start on November 25, 2026. It evaluates sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy versus the same regimen without sintilimab.
Primary source
ClinicalTrials.gov registry record, November 4, 2026
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
Read the source: Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation